Royce & Associates’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.73M | Buy |
1,389,806
+823,987
| +146% | +$2.8M | 0.05% | 469 |
|
|
2025
Q1 | $2.27M | Buy |
565,819
+95,000
| +20% | +$381K | 0.02% | 571 |
|
|
2024
Q4 | $3.06M | Buy |
470,819
+289,425
| +160% | +$1.88M | 0.03% | 562 |
|
|
2024
Q3 | $1M | Buy |
181,394
+61,916
| +52% | +$343K | 0.01% | 730 |
|
|
2024
Q2 | $667K | Buy |
119,478
+108,128
| +953% | +$603K | 0.01% | 765 |
|
|
2024
Q1 | $76.2K | Buy |
+11,350
| New | +$76.2K | ﹤0.01% | 864 |
|
|
2023
Q4 | – | Sell |
-87,489
| Closed | -$483K | – | 882 |
|
|
2023
Q3 | $483K | Buy |
87,489
+15,209
| +21% | +$84K | ﹤0.01% | 815 |
|
|
2023
Q2 | $617K | Buy |
72,280
+27,866
| +63% | +$238K | 0.01% | 811 |
|
|
2023
Q1 | $408K | Buy |
+44,414
| New | +$408K | ﹤0.01% | 859 |
|